| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Sagar Lonial | Q66431075 |
| P2093 | author name string | Nina Shah | |
| P2860 | cites work | Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma | Q43281992 |
| Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma | Q43632773 | ||
| The role of second autografts in the management of myeloma at first relapse. | Q44204181 | ||
| Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure | Q44620764 | ||
| The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis | Q45016242 | ||
| Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. | Q45918038 | ||
| Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. | Q45991042 | ||
| The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. | Q46646179 | ||
| Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy | Q46733366 | ||
| Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma | Q46735730 | ||
| Low dose Velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients | Q46830779 | ||
| Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma | Q79407795 | ||
| Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy | Q80277048 | ||
| Second autologous transplantation for multiple myeloma patients relapsing after the first autograft -- a pilot study for the evaluation of experimental maintenance therapies. Report of the prospective non-randomized pilot study of the Czech Myeloma | Q80332966 | ||
| Prolonged overall survival with second on-demand autologous transplant in multiple myeloma | Q83300465 | ||
| A phase 2 study of bortezomib in relapsed, refractory myeloma | Q33348702 | ||
| A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma | Q33363081 | ||
| Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma | Q33375805 | ||
| Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression | Q33376149 | ||
| Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma | Q33377526 | ||
| Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. | Q33378895 | ||
| Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up | Q33379528 | ||
| Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma | Q33380452 | ||
| High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program | Q33382175 | ||
| Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). | Q33383048 | ||
| Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma | Q33383056 | ||
| Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma | Q33386052 | ||
| Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma | Q33386405 | ||
| Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study | Q33387077 | ||
| Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety | Q33388971 | ||
| Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. | Q33389075 | ||
| Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma | Q33401018 | ||
| Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America | Q34585268 | ||
| A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma | Q35848744 | ||
| Improved survival in multiple myeloma and the impact of novel therapies | Q36478461 | ||
| Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma | Q37375819 | ||
| Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma | Q37379984 | ||
| The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. | Q43018754 | ||
| Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice | Q43108148 | ||
| Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide | Q43115837 | ||
| Weekly bortezomib, pegylated liposomal doxorubicin, and dexamethasone is a safe and effective therapy for elderly patients with relapsed/refractory multiple myeloma | Q43132808 | ||
| Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib | Q43280884 | ||
| P921 | main subject | chemotherapy | Q974135 |
| stem cell transplantation | Q65592366 | ||
| P304 | page(s) | 310-313 | |
| P577 | publication date | 2010-01-01 | |
| P1433 | published in | Hematology / the Education Program of the American Society of Hematology | Q26842068 |
| P1476 | title | Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation | |
| P478 | volume | 2010 |
| Q35989943 | European perspective on multiple myeloma treatment strategies: update following recent congresses |
| Q33404749 | Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma |
| Q48402275 | Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey |
| Q47196540 | Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT. |
| Q35603152 | The immune microenvironment of myeloma |
| Q37949201 | Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents. |
Search more.